Clinical Trials Browser

OTHER × Borderline Resectable Pancreatic Cancer × Taxes × Clear all

NCT04617821 2022-01-28

AG vs mFOLFIRINOX as Neoadjuvant Therapy for Borderline Reseactable and Locally Advanced Pancreatic Cancer

Phase 3 Unknown

Gastrointestinal

Borderline Resectable Pancreatic Cancer